<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04193930</url>
  </required_header>
  <id_info>
    <org_study_id>ICSI_PR</org_study_id>
    <nct_id>NCT04193930</nct_id>
  </id_info>
  <brief_title>Different Protocols in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles</brief_title>
  <official_title>Soft Versus Conventional Protocol in Ovarian Stimulation in Intracytoplasmic Sperm Injection Cycles for Poor Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      During assisted reproduction technology treatments like in vitro fertilization, some patients
      give a poor ovarian response to controlled ovarian hyperstimulation. The European Society of
      Human Reproduction and Embryology consensus defined poor response to ovarian stimulation
      during in vitro fertilization with Bologna criteria.

      Bologna criteria: At least two of the following three features must be present:

      (i) Advanced maternal age (≥40 years). (ii) Previous Poor responders (≤3 oocytes with a
      conventional stimulation protocol).

      (iii) An abnormal ovarian reserve test Most controlled ovarian hyperstimulation regimens
      currently used for expected poor responders are based on using a high daily dose (300- 450
      IU/day) of exogenous gonadotropins. Giving a high gonadotropin dose obviously increases the
      cost of in vitro fertilization, a consequence that would be acceptable if paralleled by an
      improvement in in vitro fertilization outcome. Unfortunately, however, the available data
      suggest that increasing the daily gonadotropins dose may increase the number of retrieved
      oocytes, but not the final success rate of in vitro fertilization.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2020</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total gonadotrophins dose</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of ovarian stimulation</measure>
    <time_frame>14 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endometrial thickness</measure>
    <time_frame>14 days</time_frame>
    <description>by ultrasounds</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>ART</condition>
  <arm_group>
    <arm_group_label>Soft ovarian stimulation protocol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>conventional ovarian stimulation protocol</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <description>Oral tablet letrozole 2,5 mg/twice daily for 5 days</description>
    <arm_group_label>Soft ovarian stimulation protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Menotropins</intervention_name>
    <description>150 IU of highly purified menotropins intramuscular</description>
    <arm_group_label>Soft ovarian stimulation protocol</arm_group_label>
    <arm_group_label>conventional ovarian stimulation protocol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>recombinant Follicular stimulating hormone</intervention_name>
    <description>recombinant Follicular stimulating hormone 300- 400 IU</description>
    <arm_group_label>conventional ovarian stimulation protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Advanced maternal age (≥40 years) .

          -  Previous Poor responders (≤3 oocytes with a conventional stimulation protocol).

          -  An abnormal ovarian reserve tests

        Exclusion Criteria:

          -  Hyper or Normal responders patients.

          -  Endocrine or metabolic diseases like hyperprolactinoma, hypothyroidism,...etc

          -  Patients with a severe male factor abnormality. 4-Patients with systemic disease such
             as chronic renal disease, chronic liver disease, etc
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Women Health Hospital - Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>December 7, 2019</study_first_submitted>
  <study_first_submitted_qc>December 7, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 10, 2019</study_first_posted>
  <last_update_submitted>December 7, 2019</last_update_submitted>
  <last_update_submitted_qc>December 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Menotropins</mesh_term>
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

